Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Lung cancer biomarker testing : perspective from Europe
Avtorji:ID Thunnissen, Erik (Avtor)
ID Weynand, Birgit (Avtor)
ID Udovicic-Gagula, Dalma (Avtor)
ID Brčić, Luka (Avtor)
ID Szolkowska, Malgorzata (Avtor)
ID Hofman, Paul (Avtor)
ID Smojver-Ježek, Silvana (Avtor)
ID Anttila, Sisko (Avtor)
ID Calabrese, Fiorella (Avtor)
ID Kern, Izidor, Klinika Golnik (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (1,80 MB)
MD5: 08500071FD4E2273A0DACAEECA7E7FDB
 
URL URL - Izvorni URL, za dostop obiščite http://tlcr.amegroups.com/article/view/40413/pdf
 
Jezik:Angleški jezik
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:Logo UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
Povzetek:A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26-28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long-term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future.
Ključne besede:lung neoplasms -- diagnosis -- therapy -- Europe, lung cancer, predictive testing
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Kraj izida:Kitajska
Založnik:AME Publishing
Leto izida:2020
Št. strani:str. 887-897
Številčenje:Vol. 9, iss. 3
PID:20.500.12556/DiRROS-12421 Novo okno
UDK:616-006
ISSN pri članku:2226-4477
COBISS.SI-ID:28071683 Novo okno
Avtorske pravice:© Translational Lung Cancer Research
Opomba:Nasl. z nasl. zaslona; Soavtor iz Slovenije: Izidor Kern; Opis vira z dne 11. 9. 2020;
Datum objave v DiRROS:21.09.2020
Število ogledov:2457
Število prenosov:1342
Metapodatki:XML DC-XML DC-RDF
:
THUNNISSEN, Erik, WEYNAND, Birgit, UDOVICIC-GAGULA, Dalma, BRČIĆ, Luka, SZOLKOWSKA, Malgorzata, HOFMAN, Paul, SMOJVER-JEŽEK, Silvana, ANTTILA, Sisko, CALABRESE, Fiorella in KERN, Izidor, 2020, Lung cancer biomarker testing : perspective from Europe. Translational lung cancer research [na spletu]. 2020. Vol. 9, no. 3, p. 887–897. [Dostopano 4 april 2025]. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=12421
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Translational lung cancer research
Skrajšan naslov:Transl. lung cancer res.
Založnik:Pioneer Bioscience
ISSN:2226-4477
COBISS.SI-ID:17120003 Novo okno

Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.
Začetek licenciranja:27.05.2020

Sekundarni jezik

Jezik:Ni določen
Ključne besede:pljučne novotvorbe -- diagnostika -- terapija -- Evropa, pljučni rak, napovedno testiranje


Nazaj